An Observational Study in Subjects to Follow the Progression of Stargardt Disease Type 1 (STGD1) Caused by Bi-Allelic Autosomal Recessive Mutations in the ATP Binding Cassette Subfamily A Member 4 (ABCA4) Gene (POLARIS)
Karo Barsamian
DRCR AL
A Randomized Clinical Trial Evaluating Intravitreal Faricimab (6.0 mg) Injections or Fluocinolone Acetonide (0.19 mg) Intravitreal Implants vs Observation for Prevention of Visual Acuity Loss due to Radiation Retinopathy (Protocol AL)
DRCR AO
Home OCT-Guided Treatment versus Treat and Extend for the Management of Neovascular AMD (Protocol AO)
A Conversation with Visiting Student Jesus Melendez-Montañez
Jesus Melendez-Montañez, a medical student from Ponce School of Medicine at Ponce Health Sciences University, recounts his experience with the Department of Ophthalmology and Visual Sciences (DOVS) during his rotation as a visiting student. …
A Conversation with Visiting Student Alana Bryant
Alana Bryant, a medical student from Meharry Medical College, shared her insights and experiences from her recent rotation with the Department of Ophthalmology and Visual Sciences (DOVS) as a visiting student. Bryant’s journey to …
NEXPEDE-1
A Randomized, Multicenter, Double-Masked, Vehicle-Controlled Phase 2/3 Study to Evaluate the Safety and Efficacy of NEXAGON (Lufepirsen Ophthalmic Gel) in Subjects with Persistent Corneal Epithelial Defects (NEXPEDE-1).
KOWA 303
A Double-Masked, Randomized, Placebo-Controlled, Parallel-Group, 12-Week Administration With Two-Week Gradual Dose Taper and 38-Week Follow-Up Phase, Phase 3 Study to Investigate the Safety and Efficacy of Ripasudil (K-321) Eye Drops After Simultaneous Cataract Surgery and Descemetorhexis in Subjects With Fuchs Endothelial Corneal Dystrophy (FECD).
KOWA 301
A Double-Masked, Randomized, Placebo-Controlled, Parallel-Group, 12-Week Administration With Two-Week Gradual Dose Taper Phase and 38-Week Follow-Up Phase, Phase 3 Study to Investigate the Safety and Efficacy of Ripasudil (K-321) Eye Drops After Descemetorhexis in Subjects With Fuchs Endothelial Corneal Dystrophy (FECD).
AURA 301
A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects with Primary Intermediate Lesions or Small Choroidal Melanoma.